Cinctive Capital Management LP Has $1.15 Million Position in West Pharmaceutical Services, Inc. $WST

Key Points

• Cinctive Capital Management LP significantly reduced its holdings in West Pharmaceutical Services by 68.0%, now owning just 5,140 shares valued at approximately $1.15 million.
• West Pharmaceutical Services reported earnings of $1.84 per share, exceeding estimates by $0.33, alongside a revenue of $766.50 million for the quarter, up 9.2% year-over-year.
• The company increased its quarterly dividend to $0.22 per share, marking a positive change from the previous $0.21, with a dividend yield of 0.4%.

Cinctive Capital Management LP decreased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 68.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,140 shares of the medical instruments supplier's stock after selling 10,911 shares during the quarter. Cinctive Capital Management LP's holdings in West Pharmaceutical Services were worth $1,151,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in WST. Boston Trust Walden Corp boosted its position in shares of West Pharmaceutical Services by 4.7% in the first quarter. Boston Trust Walden Corp now owns 1,110 shares of the medical instruments supplier's stock valued at $249,000 after acquiring an additional 50 shares during the period. Nissay Asset Management Corp Japan ADV increased its position in West Pharmaceutical Services by 0.6% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 9,318 shares of the medical instruments supplier's stock worth $3,105,000 after acquiring an additional 55 shares during the period. Formidable Asset Management LLC raised its stake in West Pharmaceutical Services by 2.7% during the 4th quarter. Formidable Asset Management LLC now owns 2,067 shares of the medical instruments supplier's stock valued at $677,000 after purchasing an additional 55 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in West Pharmaceutical Services by 0.7% in the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 7,887 shares of the medical instruments supplier's stock valued at $1,766,000 after purchasing an additional 57 shares during the period. Finally, Horizon Investments LLC grew its position in West Pharmaceutical Services by 5.8% in the 1st quarter. Horizon Investments LLC now owns 1,048 shares of the medical instruments supplier's stock worth $234,000 after purchasing an additional 57 shares during the last quarter. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Price Performance

Shares of NYSE WST traded down $0.98 during midday trading on Tuesday, reaching $252.17. 430,213 shares of the company traded hands, compared to its average volume of 821,962. The stock's 50-day simple moving average is $238.29 and its 200-day simple moving average is $224.45. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.08 and a current ratio of 2.78. West Pharmaceutical Services, Inc. has a 12 month low of $187.43 and a 12 month high of $352.33. The firm has a market cap of $18.13 billion, a PE ratio of 37.75, a PEG ratio of 4.45 and a beta of 1.05.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical instruments supplier reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.33. The firm had revenue of $766.50 million during the quarter, compared to the consensus estimate of $725.11 million. West Pharmaceutical Services had a net margin of 16.48% and a return on equity of 18.43%. The firm's quarterly revenue was up 9.2% on a year-over-year basis. During the same period last year, the firm posted $1.52 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 6.650-6.850 EPS. As a group, equities analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 19th. Investors of record on Wednesday, November 12th will be issued a $0.22 dividend. This is a positive change from West Pharmaceutical Services's previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Wednesday, November 12th. West Pharmaceutical Services's dividend payout ratio (DPR) is presently 12.57%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Wall Street Zen raised shares of West Pharmaceutical Services from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Citigroup reaffirmed a "buy" rating on shares of West Pharmaceutical Services in a report on Thursday, May 22nd. Evercore ISI raised their price objective on West Pharmaceutical Services from $275.00 to $350.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. UBS Group boosted their price objective on West Pharmaceutical Services from $285.00 to $320.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Finally, Barclays assumed coverage on West Pharmaceutical Services in a research note on Tuesday, June 24th. They issued an "equal weight" rating and a $245.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, West Pharmaceutical Services has a consensus rating of "Moderate Buy" and an average target price of $320.71.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.